U.S. Patent 7,732,490: Vorinostat Dosage, Cancer-Method Claims and Patent Landscape

U.S. Patent No. 7,732,490 covers oral administration of suberoylanilide hydroxamic acid, known as SAHA or vorinostat, at doses up to 400 mg for treating cancer. Its principal commercial relevance is a dose-and-use claim set rather than protection for vorinostat itself, its molecular structure, a formulation, or a manufacturing process. The patent claims 200 mg daily, 400 mg daily, and, for non-Hodgkin's lymphoma, 200 mg twice daily.

The claims are narrow in administration route and dosing but broad in disease coverage. They do not require a particular tablet formulation, excipient, treatment duration, biomarker, line of therapy, or combination agent.

What does U.S. Patent 7,732,490 protect?

The patent protects treatment methods requiring the following core elements:

Claim element	Scope
Active ingredient	Suberoylanilide hydroxamic acid, or SAHA, also called vorinostat
Route	Oral administration
Patient	A patient with cancer
Dose	Generally up to 400 mg as a single therapeutically effective dose
Specific regimens	200 mg daily, 400 mg daily, or 200 mg twice daily for non-Hodgkin's lymphoma
Dosage form	Not limited to a particular tablet, capsule, coating, excipient, or release profile
Salt or hydrate	Pharmaceutically acceptable salt or hydrate is included in the broader claims
Disease scope	Lung cancer, non-Hodgkin's lymphoma, myeloma, breast carcinoma, ovarian carcinoma, and listed additional cancers

The independent claims are claims 1, 4, 5, 8, 11, 14, and 33. Claims 17 through 74 largely repeat earlier claims by specifying that SAHA, rather than a salt or hydrate, is administered or by restating daily and dose limitations.

What is excluded from the claim scope?

The claims do not expressly cover:

Intravenous or injectable vorinostat;
A specific crystalline form;
A particular particle size;
A controlled-release or enteric-coated formulation;
A manufacturing process;
A method of treating cutaneous T-cell lymphoma by name;
A combination regimen with another anticancer drug;
A required treatment duration;
A defined patient biomarker or mutation;
A pharmacokinetic target;
A specific commercial product.

A product may therefore fall outside these claims if it is administered by a nonoral route, used for a disease outside the recited scope, or administered under a regimen that does not satisfy the relevant dose limitation.

How are the independent claims structured?

Claims 1 and 33: broad cancer treatment claims

Claim 1 covers oral administration of a single therapeutically effective dose of up to 400 mg of SAHA for lung cancer. Claim 33 covers the same general dosing concept for cancer without the disease-specific limitation.

Claim 33 is the broadest claim on its face because it does not identify a particular cancer type. Its practical scope is still limited by the oral route, the SAHA identity, and the dose ceiling.

The phrase "up to 400 mg" potentially covers doses below 400 mg, subject to the requirement that the dose be therapeutically effective. Claims 34 and 35 narrow the regimen to 200 mg daily and 400 mg daily.

Claim 4: non-Hodgkin's lymphoma

Claim 4 covers oral administration of 200 mg twice daily for non-Hodgkin's lymphoma. This is a total daily dose of 400 mg, but the claim requires divided administration rather than one 400 mg dose.

This distinction matters. A 400 mg once-daily regimen may fall within claims 33 or 35 if the other elements are met, but it does not satisfy claim 4's express twice-daily limitation.

Claims 5 through 13: myeloma, breast carcinoma and ovarian carcinoma

Claims 5, 8 and 11 apply the up-to-400-mg oral dosing concept to:

Myeloma;
Breast carcinoma; and
Ovarian carcinoma.

The dependent claims specify 200 mg daily or 400 mg daily. These claims do not require a particular subtype, disease stage, prior treatment history, or combination therapy.

Claim 14: grouped cancer indications

Claim 14 covers treatment of cancer selected from:

Colorectal carcinoma;
Hodgkin's lymphoma;
"Bladder melanoma";
Renal carcinoma; and
Prostate carcinoma.

The phrase "bladder melanoma" is unusual and may reflect an apparent drafting or transcription issue. As written, the claim should be analyzed according to the issued claim text, but its construction could become contested if asserted against treatment of bladder cancer or melanoma as separate indications.

Claims 15 and 16 narrow the dose to 200 mg daily and 400 mg daily.

How broad are the disease limitations?

The disease limitations are broad relative to the dosing limitations.

Cancer indication	Primary claim	Dose-specific dependent claims
Lung cancer	1	2, 3, 17-19, 39-44
Non-Hodgkin's lymphoma	4	20, 23, 45-50
Myeloma	5	6, 7, 21-23, 45-50
Breast carcinoma	8	9, 10, 24-26, 51-56
Ovarian carcinoma	11	12, 13, 27-29, 57-62
Colorectal carcinoma	14	15, 16, 30-32, 63-68
Hodgkin's lymphoma	14	15, 16, 30-32, 63-68
Renal carcinoma	14	15, 16, 30-32, 63-68
Prostate carcinoma	14	15, 16, 30-32, 63-68
Cancer generally	33	34, 35, 36-38, 69-74

Claim 33 presents the largest apparent disease scope. Claims 1 through 16 provide more specific disease categories that may offer fallback positions if the broad cancer claim is challenged.

What dosage regimens are protected?

The central dose limitations are:

Regimen	Claim coverage
Up to 400 mg as a single dose	Claims 1, 5, 8, 11, 14 and 33
200 mg once daily	Claims 2, 6, 9, 12, 15, 34
400 mg once daily	Claims 3, 7, 10, 13, 16, 35
200 mg twice daily	Claim 4
Daily administration without a fixed dose in the dependent claim	Claims 39, 45, 51, 57, 63 and 69
Single 200 mg dose	Claims 40, 46, 52, 58, 64 and 70
Single 400 mg dose	Claims 41, 47, 53, 59, 65 and 71

The claims create overlapping protection. A 200 mg daily treatment for lung cancer, for example, may satisfy claim 1, claim 2, claim 17, claim 18, claim 39, claim 40, and claim 43, depending on how the dependent claims are interpreted and whether their dependency is valid.

The overlapping claims do not necessarily create multiple independent infringement events. They provide alternative claim theories and can preserve narrower claims if broader claims are invalidated.

What is the claim construction risk?

"Single therapeutically effective dose"

The phrase combines a quantitative ceiling with a functional limitation. The claim does not identify a minimum dose, but the dose must be therapeutically effective for the claimed cancer.

Potential disputes include:

Whether a dose below 200 mg falls within the claim;
Whether "single dose" means a single administration event or a daily dose;
Whether a 400 mg daily regimen must be given at one time;
Whether therapeutic effectiveness must be demonstrated in the individual patient;
Whether a treatment protocol qualifies when the dose is reduced for toxicity.

The dependent claims reduce some of these disputes by specifying 200 mg daily and 400 mg daily. The functional "therapeutically effective" limitation remains relevant.

"Cancer" in claim 33

Claim 33 lacks a named cancer type. The claim may be vulnerable to enablement, written-description or indefiniteness arguments if construed to cover every cancer without adequate support in the specification. The disease-specific claims provide narrower alternatives, but they may face different support and prior-art issues.

Salt and hydrate coverage

Claims 1, 4, 5, 8, 11, 14 and 33 cover SAHA and pharmaceutically acceptable salts or hydrates. The later SAHA-only claims narrow that scope. A generic product containing the neutral vorinostat molecule would be the most direct target of the SAHA-only claims. A salt or hydrate could implicate the broader claims if it meets the pharmaceutical and administration limitations.

What is the relationship between Patent 7,732,490 and Zolinza?

Zolinza is the brand name for vorinostat, the marketed form of SAHA. Merck commercialized Zolinza for cutaneous T-cell lymphoma. The active ingredient is a small molecule, not a biologic, so biosimilar substitution rules do not apply.

The patent claims are broader than the original approved indication in some respects because they recite multiple solid tumors and hematologic malignancies. They are narrower in other respects because they require specific oral dosing conditions.

The commercial product's approved labeling is relevant to infringement analysis but does not determine claim scope. A label may support induced-infringement allegations if it directs use within a patented regimen. A label that omits a claimed indication or dose can reduce, but not necessarily eliminate, induced-infringement exposure.

What is the FDA regulatory status of vorinostat?

Vorinostat received FDA approval for treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease after systemic therapies. The FDA-approved labeling identifies Zolinza as an oral capsule product and provides a 400 mg once-daily regimen, with dose modification for toxicity and certain clinical conditions (U.S. Food and Drug Administration, 2023).

That approved regimen is commercially important because it corresponds to the 400 mg daily dosing architecture in the patent, although the principal issued claims listed by the user do not expressly recite cutaneous T-cell lymphoma. The patent's broad cancer claim and its 400 mg daily dependent claim could be asserted only if the other claim elements, including disease scope and claim construction, are satisfied.

What is the Orange Book relevance of Patent 7,732,490?

Orange Book relevance depends on whether the patent was listed for the approved drug product and whether its claims cover the approved use or an aspect of the approved product.

A method-of-use patent directed to cancers not included in the approved labeling may have limited Orange Book value for an ANDA directed to the labeled indication. Conversely, a patent covering the approved 400 mg oral regimen could be relevant if properly listed and if the generic applicant's proposed labeling overlaps the patented use.

For a small-molecule product such as vorinostat, an ANDA applicant may submit:

Paragraph I certification if no patent is listed;
Paragraph II certification if the patent has expired;
Paragraph III certification accepting expiration;
Paragraph IV certification asserting that the patent is invalid, unenforceable or not infringed; or
A section viii statement carving out a patented method of use from the proposed labeling.

The supplied claims alone do not establish the historical Orange Book listing status, the current listing status, or the certification filed by a particular generic applicant.

When does Patent 7,732,490 lose exclusivity?

U.S. patent expiration cannot be calculated reliably from the claims alone. It depends on the patent's earliest effective nonprovisional filing date, continuity chain, terminal disclaimers and any patent-term adjustment or patent-term extension.

The patent issued in 2010. A standard U.S. patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156. A patent-term extension for regulatory review is generally available for patents covering an approved product, but the extension is subject to statutory limits and product-specific requirements (35 U.S.C. §§ 154, 156).

The commercial assessment should therefore separate:

Patent expiration;
FDA regulatory exclusivity;
Orange Book listing status;
Any terminal disclaimer;
The enforceability of individual claims; and
The scope of an ANDA applicant's proposed label.

Patent expiration does not itself establish the date of generic launch. Launch also depends on litigation, settlement terms, regulatory approval and any other unexpired patents.

Which patents form the broader vorinostat patent estate?

The relevant patent estate generally falls into four groups.

Composition-of-matter patents

Earlier SAHA or hydroxamic-acid HDAC inhibitor patents may cover the molecule or broader chemical genus. These patents are distinct from Patent 7,732,490, which is directed to treatment methods and dosing.

Composition claims are usually stronger against all uses of the molecule but expire earlier when they originate from early discovery filings.

Method-of-treatment patents

Patent 7,732,490 is principally in this category. Its claims focus on cancer treatment using oral SAHA at specified doses.

Method claims can remain commercially relevant after composition claims expire, but their value depends on the approved label, physician prescribing behavior and the ability to prove direct or induced infringement.

Formulation patents

A separate formulation patent could cover:

Tablet composition;
Capsule composition;
Stabilization;
Dissolution profile;
Bioavailability enhancement;
Solid-state form;
Particle engineering; or
Modified release.

The claims supplied for Patent 7,732,490 contain no formulation limitation. They therefore should not be treated as formulation protection.

Manufacturing and process patents

Process patents may cover synthesis, purification, crystallization or intermediate compounds. They can create supply-chain exposure even after treatment-method patents expire, but the supplied claims do not cover manufacturing conduct.

How strong is the patent estate for generic entry?

Patent 7,732,490 has a mixed strength profile.

Factor	Assessment
Molecule coverage	Low under the supplied claims; the claims do not broadly claim vorinostat itself
Route coverage	Strongly limited to oral administration
Dose coverage	Focused on up to 400 mg and 200 mg or 400 mg daily
Indication coverage	Broad across named cancers and claim 33's general cancer language
Formulation coverage	None apparent
Manufacturing coverage	None apparent
Biosimilar relevance	None; vorinostat is a small molecule
ANDA relevance	Potentially meaningful if the proposed label includes a claimed use
Physician-practice dependence	High, because infringement depends on actual treatment use and instructions
Invalidity exposure	Potential issues include written description, enablement, obviousness, indefiniteness and anticipation

The strongest commercial position would arise where a generic label expressly recommends oral vorinostat at 400 mg daily for a claimed cancer indication. The position is weaker where the generic label is limited to an unclaimed indication, omits the patented dosing instruction, or relies on a section viii carve-out.

What Paragraph IV challenges and litigation affect the patent?

A complete Paragraph IV and litigation assessment requires the ANDA applicant, FDA Orange Book records and PACER or court docket data. The claim text does not identify:

The patent owner or current assignee;
Any ANDA applicant;
The date of a Paragraph IV notice;
A district-court action;
A declaratory-judgment action;
A settlement agreement;
A 30-month stay;
A launch-at-risk event; or
A final judgment affecting validity or enforceability.

The statutory framework is governed principally by the Hatch-Waxman Act and 21 U.S.C. § 355(j). A Paragraph IV certification can trigger patent litigation if the patent owner files suit within the statutory period. A settlement may establish a licensed entry date, authorized-generic arrangement, or restrictions on the generic's label, but no settlement terms can be inferred from the claims.

What generic launch scenarios exist for vorinostat?

Label overlap

If a generic applicant's labeling instructs treatment of a claimed cancer at 200 mg daily, 400 mg daily or 200 mg twice daily, the applicant faces potential method-of-use exposure.

Section viii carve-out

A generic applicant may seek approval for uses that can be carved out of the labeling. This route is more practical if the patented uses are separable from the nonpatented approved use and the FDA-approved label can omit the claimed method.

Paragraph IV litigation

An applicant may challenge the patent by arguing:

The claims are anticipated by earlier clinical or scientific disclosures;
The claimed dose would have been obvious;
The specification does not support the breadth of the disease claims;
"Therapeutically effective dose" is indefinite;
The claims are not enabled across the full cancer scope;
The patent is unenforceable because of inequitable conduct; or
The proposed generic use does not practice every claim limitation.

Launch after expiration

If no other blocking patent remains and FDA approval is complete, entry may occur after patent expiration or under an agreed settlement date.

How does Patent 7,732,490 compare with formulation or composition patents?

Patent type	Typical protection	Exposure created by generic vorinostat
Composition-of-matter	The active molecule or chemical genus	Broadest product-use exposure
Method-of-use	Treatment indication, route and dose	Depends on label and clinical use
Formulation	Tablet, capsule, excipient or release profile	Can be avoided through alternative formulation
Process	Synthesis or purification	Depends on supplier and manufacturing route
Patent 7,732,490	Oral SAHA treatment at specified doses	Narrower than composition claims, broader than formulation claims in disease coverage

Patent 7,732,490 does not prevent every sale or use of vorinostat. It targets particular oral treatment methods. A generic may avoid infringement of an individual claim by changing the labeled indication, dose, route, or dosing schedule, subject to FDA requirements and the scope of other patents.

What licensing and ownership issues matter?

Commercial analysis should verify the full assignment and licensing chain. SAHA was associated with academic and institutional research, while Zolinza commercialization involved pharmaceutical-industry licensing and development arrangements. Ownership of a patent can differ from the identity of the brand sponsor, manufacturer or marketing authorization holder.

The relevant diligence points are:

Recorded assignments at the USPTO;
Exclusive or nonexclusive licenses;
Government rights arising from federally funded research;
Co-ownership obligations;
Sublicense rights;
Patent-maintenance fee status;
Terminal disclaimers; and
Any covenant not to sue or settlement license.

No license terms, assignment chain or settlement rights are stated in the supplied patent claims.

Key Takeaways

Patent 7,732,490 is a method-of-treatment patent for oral SAHA, or vorinostat.
Its main limitations are the oral route, cancer treatment, and doses up to 400 mg.
The patent specifically claims 200 mg daily, 400 mg daily and 200 mg twice daily for non-Hodgkin's lymphoma.
It does not claim the vorinostat molecule itself, a specific formulation, a solid-state form or a manufacturing process.
Claim 33 is the broadest apparent disease claim because it recites cancer generally.
The claims cover several cancers not included in the original principal FDA indication for Zolinza.
Generic risk depends heavily on proposed labeling and whether the label can carve out patented uses.
Vorinostat is a small molecule, so biosimilar pathways are not relevant.
The claims alone do not establish current patent expiration, Orange Book listing, Paragraph IV activity, litigation status or settlement terms.
A complete freedom-to-operate opinion requires review of the full patent family, prosecution history, assignment records, Orange Book data, ANDA certifications and litigation dockets.

FAQs

Does Patent 7,732,490 cover all uses of vorinostat?

No. The supplied claims require oral administration for cancer treatment and impose dose-related limitations. They do not broadly claim every use, formulation or manufacturing process involving vorinostat.

Does a 400 mg once-daily vorinostat regimen fall within the patent?

It may fall within the 400 mg daily dependent claims if the treated cancer and all other claim elements are satisfied. It does not meet the separate 200 mg twice-daily limitation in claim 4.

Can a generic manufacturer avoid the patent by using a different tablet formulation?

Possibly, because the supplied claims do not require a particular formulation. A different formulation would not avoid the claims if the generic still practices the claimed oral dosing method, but it could avoid separate formulation claims in another patent.

Is cutaneous T-cell lymphoma covered by these claims?

The claims provided do not expressly name cutaneous T-cell lymphoma. Claim 33 recites cancer generally, but the scope and enforceability of that broad language would depend on claim construction and validity analysis.

Does Patent 7,732,490 create biosimilar risk?

No. Vorinostat is a chemically synthesized small molecule. Generic-drug and Hatch-Waxman analysis, not biosimilar analysis under the Biologics Price Competition and Innovation Act, is the applicable framework.

References

U.S. Food and Drug Administration. (2023). Zolinza (vorinostat) prescribing information.
United States Code. (2024). 21 U.S.C. § 355: New drugs.
United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
United States Code. (2024). 35 U.S.C. § 156: Extension of patent term.
U.S. Patent No. 7,732,490. (2010). Methods of treating cancer using suberoylanilide hydroxamic acid. U.S. Patent and Trademark Office.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	462426	⤷ Start Trial
Australia	2003213684	⤷ Start Trial
Australia	2004266169	⤷ Start Trial
Australia	2004283717	⤷ Start Trial
Australia	2008246251	⤷ Start Trial
Australia	2009201668	⤷ Start Trial
Brazil	0308250	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,732,490